REPERFUSION TREATMENT MARKET ANALYSIS

Market News

Global Reperfusion Treatment Market: Key Developments

On January 25, 2021, PEDRA Technology, a company developing perfusion technologies, announced that the U.S. FDA had provide the company a Breakthrough Device Designation for the periprocedural use of its PEDRA Xauron Perfusion System in the treatment of critical limb-threatening ischemia (CLTI). As a result of persistently inadequate blood flow to the lower limbs, CLTI, a severe form of peripheral artery disease (PAD), reported ischemic rest discomfort, tissue loss, or gangrene (tissue death). Untreated CLTI can result in amputation of a limb or death. The death rate is higher than that of most malignancies at five years after the diagnosis of CLTI.

On September 15, 2020, Transcenta, a global biotherapeutics company, announced it had successful scaled up the continuous perfusion process and completed good manufacturing practice (GMP) manufacturing of a novel bispecific antibody for cancer immunotherapy.

Global Reperfusion Treatment Market: Key Trends

Increasing research and development activities

Increasing research and development related to perfusion treatment can drive growth of the market. On January 18, 2023, Journal of Hepatology published an article explaining that machine perfusion is a novel method which is intended to optimize livers before transplantation. However, its effect on morbidity within a 1-year period after transplantation has remained unclear. In this multicenter controlled  clinical trial, researchers randomly assigned livers donated after brain death (DBD) for liver transplantation (LT). Livers were either conventionally cold stored (control group) or cold stored and subsequently treated by 1-2 hypothermic oxygenated perfusions (HOPE) before implantation (HOPE group).